Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Return to homepage

Lattice Biologics Ltd. (V:LBL)

Business Focus: Medical Devices & Implants

Get the company report for the most recent outlook updated daily
Jul 09, 2021 02:02 pm ET
Lattice Biologics Ltd. Reports Second Quarter 2021 Results and Resumes Trading
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces financial results for Q2 2021.
Jun 07, 2021 07:57 am ET
IIROC Trading Halt - LBL
VANCOUVER, BC, June 7, 2021 /CNW/ - The following issues have been halted by IIROC:
Mar 31, 2021 07:00 am ET
Lattice Announces Strategic Advisory Board
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice” or the “Company”), an emerging leader in psilocybin research and cannabis company, today announced the formation of its Strategic Advisory Board, a group of respected business leaders that will provide guidance to Lattice’s executive team as i
Mar 19, 2021 11:33 am ET
Lattice Announces Strategic Cannabis Supply Agreement With Firehouse
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice” or the “Company”), an emerging leader in psilocybin research and cannabis company, today announced it has entered into a Strategic Supply Agreement (the "Agreement") with Firehouse LLC ("Firehouse"), one of M
Mar 15, 2021 07:30 am ET
Lattice Biologics Reorganizes to Focus on Psychedelics and Cannabis Therapies
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announced today that the Company will change its business strategy to focus on the fast growing psychedelics and cannabis markets through the creation of a new life sciences subsidiary. The Comp
Mar 03, 2021 05:18 pm ET
Lattice Biologics Ltd. Announces Resignation of Director
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces that Mr. Donald McInnes has resigned as a director of the Company, effective immediately, so that he can focus his efforts on other professional commitments.
Mar 01, 2021 06:40 pm ET
Lattice Biologics Ltd. Reports First Quarter 2021 Highlights
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces financial results for Q1 2021.
Jan 28, 2021 10:00 pm ET
 Lattice Biologics Ltd. Reports Fourth Quarter and Year End 2020 Highlights
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces financial results for Q4 2020 and year end 2020.
Jan 05, 2021 10:16 pm ET
Lattice Unaware of Any Material Change
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) at the request of the Investment Industry Regulatory Organization of Canada (“IIROC”), wishes to confirm that it is not aware of any material, undisclosed information related to the Company that
Sep 03, 2020 12:09 am ET
COVID19 UPDATE – Lattice Biologics Announces Cessation of Patient Recruitment
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces cessation of patient recruitment for its Phase 1 study.
Aug 31, 2020 07:53 pm ET
Lattice Biologics Ltd. Reports Q3 2020 Results
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces financial results for Q3 2020.
Aug 18, 2020 10:53 am ET
Lattice Biologics Issues Shares and Warrants
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) has issued common shares and warrants pursuant to a litigation settlement.
Jun 08, 2020 07:28 pm ET
Lattice Biologics Eliminates CAN$838,000 in Debt
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) is pleased to announce that it has obtained TSX-V approval to issue 16,760,000 common shares of the Company to settle outstanding debt.
Jun 02, 2020 09:00 am ET
Lattice Biologics Ltd. Reports Second Quarter 2020 Results
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces financial results for Q2 2020
May 11, 2020 09:00 am ET
Lattice Biologics Update
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) is pleased to announce the addition of Chad Green, RRT, to the clinical development team. Mr. Green is a registered respiratory therapist, and President- elect of the Montana chapter of respiratory therapists. Mr. G
Apr 15, 2020 12:32 pm ET
Lattice Biologics Ltd. Announces Option Repricing
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces that the Company has repriced the strike price of the 3 million stock options originally to be granted to Directors and Employees announced on March 16, 20
Apr 07, 2020 12:29 am ET
Lattice Biologics Signs Definitive Agreement with Alumina Partners for $6 Million At-Will Offering Facility
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) is pleased to announce that it has entered into a definitive agreement (the "Agreement") with Alumina Partners (Ontario) Ltd. ("Alumina") for a commitment of up to $6,000,0
Mar 17, 2020 08:00 am ET
Lattice Biologics Ltd. Announces Initial Recruitment of Patients for a Phase 1 Clinical Trial to Access Safety and Efficacy of AmnioBoost for Treatment of COVID-19
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces it has begun enrolling patients in its Phase 1 clinical trial to address safety and efficacy of its novel stem cell technology, AmnioBoost, for the treatment of severe acute re
Mar 13, 2020 07:00 am ET
Lattice Biologics to Evaluate Anti-Inflammatory Stem Cell Therapy Treatment of COVID-19 Lung Disease
Lattice Biologics Ltd. (TSX-V: LBL) (
Mar 11, 2020 05:58 pm ET
Lattice Biologics Announces Planned Debt-to-Equity Conversion
Lattice Biologics Ltd. (TSX-V: LBL) (
Mar 03, 2020 05:00 pm ET
LATTICE BIOLOGICS LTD. Transferred To TSX Venture Exchange Tier 2
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) Lattice Biologics Ltd. announces today that its listing on the TSX Venture Exchange (“TSX-V”) has been transferred from the Tier 1 category to the Tier 2 category effective March 5, 2020
Feb 28, 2020 08:00 am ET
Lattice Biologics Ltd. Reports Q1 2020 Results
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces financial results for Q1 2020.
Jan 28, 2020 11:00 pm ET
Lattice Biologics Ltd. Reports Year End 2019 Results and Q1 Preliminary Q1 2020 Revenues
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces financial results for the fiscal year end 2019 and preliminary revenues for Q1 2020.
Aug 29, 2019 08:15 am ET
Lattice Biologics Ltd. Reports Third Quarter 2019 Results
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces financial results for Q3 2019.
May 31, 2019 01:14 am ET
Lattice Biologics Ltd. Reports Second Quarter 2019 Results
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces financial results for Q2 2019.
Mar 01, 2019 11:05 am ET
Lattice Biologics Ltd. Reports First Quarter 2019 Results
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces financial results for Q1 2019, and preliminary revenues for Q2 2019.
Jan 29, 2019 08:00 am ET
Lattice Biologics Ltd. Reports Year End 2018 Results
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces financial results for the fiscal year end 2018 and preliminary revenues for Q1 2019.
Aug 30, 2018 04:00 pm ET
Lattice Biologics Ltd. Reports Third Quarter 2018 Results
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces financial results for the three and nine months ending June 2018.
May 30, 2018 09:00 am ET
Lattice Biologics Ltd. Reports Second Quarter 2018 Highlights
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces financial results for the second quarter 2018.
May 14, 2018 09:00 am ET
Lattice Biologics Ltd. Announces Management Cease Trading Order is Revoked
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces the Company has successfully filed all necessary reporting documents and the preceding MCTO was revoked as of May 1, 2018.
Apr 30, 2018 08:00 pm ET
Lattice Biologics Ltd. Reports Fourth Quarter 2017, First Quarter 2018, and Year End 2017 Highlights
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces financial results for the fourth quarter 2017, year ended September 30, 2017, and first quarter 2018:
Apr 25, 2018 04:00 pm ET
Lattice Biologics Ltd. Announces Update to Management Cease Trade Order
Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBL
Apr 11, 2018 04:00 pm ET
Lattice Biologics Ltd. Announces Update to Management Cease Trade Order
Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBL
Mar 28, 2018 04:00 pm ET
Lattice Biologics Ltd. Announces Update to Management Cease Trade Order
Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBL
Mar 28, 2018 09:00 am ET
Update March 28, 2018: Lattice Biologics Ltd. Management Cease Trade Order
Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBL
Mar 14, 2018 09:00 am ET
Update March 14, 2018: Lattice Biologics Ltd. Management Cease Trade Order
Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBL
Feb 28, 2018 09:00 am ET
Update February 28, 2018: Lattice Biologics Ltd. Cease Trade Order
Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBL
Feb 14, 2018 09:00 am ET
Lattice Biologics Ltd. Announces Management Cease Trade Order
Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBL
Jan 30, 2018 09:00 am ET
Lattice Biologics Ltd. Announces Management Cease Trade Order
Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBL
Dec 22, 2017 04:06 pm ET
Lattice Biologics Ltd. Announces Change in Director and Change in Status of Chief Operating Officer
Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBL
Jun 20, 2017 04:30 pm ET
Lattice Biologics Ltd. Announces Change to Location of Its Annual General and Special Meeting
Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCQB: LBLTF) ("Lattice Biologics" or the "Company") announces that due to increased shareholder interest it is changing the location of its Annual General and Special Meeting to accommodate greater...
Jun 13, 2017 04:30 pm ET
Lattice Biologics Ltd. Announces Completion of Transaction to Reduce Royalty and Debt Obligations
Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCQB: LBLTF) ("Lattice Biologics" or the "Company") announced today that it has completed the previously announced transaction to significantly reduce the Company's royalty and debt obligations (the...
Jun 01, 2017 04:48 pm ET
Lattice Biologics Ltd. Receives Multi-Year American Association of Tissue Banks Re-Accreditation
Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCQB: LBLTF) ("Lattice Biologics" or the "Company") is pleased to announce that it has been approved for re-accreditation by the American Association of Tissue Banks ("AATB") for processing, storage, and...
May 31, 2017 04:30 pm ET
Lattice Biologics Ltd. Appoints Chief Operating Officer
Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCQB: LBLTF) (the "Company") is pleased to announce the appointment of Darrel Holmes as Chief Operating Officer of the Company, effective May 30, 2017.Mr. Holmes is a seasoned executive with over 30 years...
May 30, 2017 06:22 pm ET
Lattice Biologics Ltd. Reports Second Quarter 2017 Highlights
Lattice Biologics Ltd. (TSX VENTURE:LBL) (OTCQB:LBLTF) ("Lattice Biologics" or the "Company") announces financial results for the second quarter ended March 31, 2017: Highlights: New sales team focused on...
May 30, 2017 06:22 pm ET
Lattice Biologics Ltd. Reports Second Quarter 2017 Highlights
Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCQB: LBLTF) ("Lattice Biologics" or the "Company") announces financial results for the second quarter ended March 31, 2017:
May 17, 2017 04:30 pm ET
Notice of Lattice Biologics Ltd. Second Quarter 2017 Financial Results Conference Call
Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCQB: LBLTF) (the "Company") announced today that it will release its second quarter 2017 financial results after market on Tuesday, May 30, 2017. Following this, Guy Cook, Chief Executive Officer, and...
May 15, 2017 04:30 pm ET
Lattice Biologics Announces Completion of Private Placement
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICESLattice Biologics Ltd. (TSX VENTURE: LBL) (OTCQB: LBLTF) ("Lattice Biologics" or the "Company") is pleased to announce that it has closed the previously announced non-brokered private...
Apr 26, 2017 04:00 pm ET
Lattice Biologics Announces Agreement to Successfully Reduce Royalty and Debt Obligations
Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCQB: LBLTF) ("Lattice Biologics" or the "Company") is pleased to announce that it has entered into an agreement to successfully extinguish approximately US$2.8 million of debt under its royalty purchase...
Apr 04, 2017 04:45 pm ET
Lattice Biologics Closes Fifth Tranche of Private Placement and Extends Funding Raise for an Additional 30 Days
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICES Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCQB: LBLTF) ("Lattice Biologics" or the "Company") is pleased to announce that it has closed the fifth tranche of its non-brokered private...
Mar 20, 2017 08:30 am ET
Service Provider Loyalty Remains Strong as Lattice Biologics Issues Shares for Services and Announces Planned Debt-to-Equity Conversion
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICESLattice Biologics Ltd. (TSX VENTURE: LBL) (OTCQB: LBLTF) ("Lattice Biologics" or the "Company") is pleased to announce that it has obtained TSX Venture Exchange ("TSXV") approval to...
Mar 07, 2017 04:47 pm ET
Lattice Biologics Extends Private Placement
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICESLattice Biologics Ltd. (TSX VENTURE: LBL) (OTCQB: LBLTF) ("Lattice Biologics" or the "Company") announces that it is extending its non-brokered private placement of Units of the Company...
Mar 01, 2017 05:14 pm ET
Lattice Biologics Ltd. Reports First Quarter 2017 Highlights
Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCQB: LBLTF) ("Lattice Biologics" or the "Company") announces financial results for the first quarter ended December 31, 2016:
Mar 01, 2017 05:14 pm ET
Lattice Biologics Ltd. Reports First Quarter 2017 Highlights
Lattice Biologics Ltd. (TSX VENTURE:LBL) (OTCQB:LBLTF) ("Lattice Biologics" or the "Company") announces financial results for the first quarter ended December 31, 2016: Highlights: Record Gross Margins...
Feb 28, 2017 05:02 pm ET
Lattice Biologics Participates in $300 Million Public-Private Initiative, the Advanced Regenerative Manufacturing Institute (ARMI)
Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCQB: LBLTF) ("Lattice Biologics" or the "Company") is pleased to announce that it is part of a new public-private initiative, the Advanced Regenerative Manufacturing Institute ("ARMI"). ARMI will receive...
Feb 28, 2017 04:50 pm ET
Lattice Biologics Closes Fourth Tranche of Private Placement Announced on January 19, 2017
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICESLattice Biologics Ltd. (TSX VENTURE: LBL) (OTCQB: LBLTF) ("Lattice Biologics" or the "Company") is pleased to announce that it has closed the fourth tranche of its non-brokered private...
Feb 16, 2017 04:30 pm ET
Lattice Biologics Closes Third Tranche of Private Placement Announced on January 19, 2017
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICESLattice Biologics Ltd. (TSX VENTURE: LBL) (OTCQB: LBLTF) ("Lattice Biologics" or the "Company") is pleased to announce that it has closed the third tranche of its non-brokered private...
Feb 14, 2017 08:30 am ET
Notice of Lattice Biologics Ltd. First Quarter 2017 Financial Results Conference Call
Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCQB: LBLTF) (the "Company") announced today that it will release its first quarter 2017 financial results after market on Wednesday, March 1, 2017. Following this, Guy Cook, Chief Executive Officer, and...
Feb 01, 2017 04:30 pm ET
Lattice Biologics Upgraded to OTCQB Venture Market
Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCQB: LBLTF) ("Lattice Biologics" or the "Company") is pleased to announce that the Company has been approved to upgrade its common shares from the Pink Open Market to the OTCQB® Venture Market under the...
Jan 30, 2017 07:08 pm ET
Lattice Biologics Ltd. Reports Fourth Quarter and Year End 2016 Highlights
Lattice Biologics Ltd. (TSX VENTURE:LBL) (OTCBB:LBLTF)("Lattice Biologics" or the "Company") announces financial results for the fourth quarter and year ended September 30, 2016: Highlights: DBM Putty growth...
Jan 30, 2017 07:08 pm ET
Lattice Biologics Ltd. Reports Fourth Quarter and Year End 2016 Highlights
Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: LBLTF)("Lattice Biologics" or the "Company") announces financial results for the fourth quarter and year ended September 30, 2016:
Jan 27, 2017 06:34 pm ET
Notice of Lattice Biologics Ltd. Year End 2016 Financial Results Conference Call
Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: LBLTF) (the "Company") announced today that it will release its year ended September 30, 2016 financial results after market on Monday, January 30, 2017. Following this, Guy Cook, Chief Executive...
Jan 26, 2017 08:30 am ET
Lattice Biologics Closes Second Tranche of Private Placement Announced on January 19, 2017
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICESLattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: LBLTF) ("Lattice Biologics" or the "Company") is pleased to announce that it has closed the second tranche of the non-brokered private...
Jan 24, 2017 08:30 am ET
Lattice Biologics Closes First Tranche of Private Placement Announced on January 19, 2017
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICESLattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: LBLTF) ("Lattice Biologics" or the "Company") is pleased to announce that it has closed the first tranche of the non-brokered private...
Jan 19, 2017 05:31 pm ET
Lattice Biologics Announces New Private Placement
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICESLattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: LBLTF) ("Lattice Biologics" or the "Company") is pleased to announce a new private placement of Units of the Company ("Units") at a...
Jan 05, 2017 08:10 pm ET
Lattice Biologics Issues Common Shares
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICESLattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) ("Lattice Biologics" or the "Company") is pleased to announce that it has obtained TSX Venture Exchange ("TSXV") approval to...
Dec 08, 2016 08:30 am ET
Lattice Biologics Issues New Common Shares, Extinguishing Significant Outstanding Debt
Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) ("Lattice" or the "Company") is pleased to announce that it has issued new common shares and eliminated significant debt.Pursuant to the Company's news release issued November 10, 2016, which...
Dec 01, 2016 08:30 am ET
Service Provider Loyalty Remains Strong as Lattice Biologics Announces Issuance of Common Shares
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICESLattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) ("Lattice" or the "Company") is pleased to announce that it has obtained TSX Venture Exchange ("TSXV") approval for the issuance...
Nov 10, 2016 08:30 am ET
Lattice Biologics Increases Size of Planned Debt-to-Equity Conversion as Investor Demand Rises
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICESLattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) ("Lattice Biologics" or the "Company") announced today that -- subject to approval by the TSX Venture Exchange -- the Company...
Nov 03, 2016 08:40 am ET
Lattice Biologics Inks Strategic Partnerships With OA Centers of America, Resilience, and Cryoport
Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) ("Lattice Biologics"), an emerging biotech leader in cellular therapies and tissue engineering, with an emphasis on bone, skin, and cartilage regeneration, is pleased to announce two new...
Nov 03, 2016 08:30 am ET
Lattice Biologics Issues 160,000+ Common Shares and Announces New Shares for Services Agreement
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICESLattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) ("Lattice Biologics" or the "Company") is pleased to announce that it has issued 63,887 common shares of the Company ("Shares")...
Oct 31, 2016 08:30 am ET
Lattice Biologics Partners With AllianceMed to Support Insurance Reimbursement for Physicians and Medical Centers
Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) ("Lattice Biologics"), an emerging biotech leader in cellular therapies and tissue engineering, with an emphasis on bone, skin, and cartilage regeneration, is pleased to announce it has formed...
Oct 25, 2016 08:30 am ET
In Response to Increasing Investor Demand, Lattice Biologics Doubles Current Private Placement for a Total of US$1,500,000
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICESLattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) ("Lattice Biologics" or the "Company") is pleased to announce that it has increased the size of its previously announced...
Oct 18, 2016 04:49 pm ET
Lattice Biologics Closes Second Tranche of Private Placement Announced on September 13, 2016
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICESLattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) ("Lattice Biologics" or the "Company") is pleased to announce that it has closed the second tranche of the non-brokered private...
Oct 11, 2016 08:15 am ET
Lattice Biologics Launches AmnioVisc(TM) All Natural Amniotic Fluid Supplement for Arthritic Joints
Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) ("Lattice Biologics" or the "Company") is pleased to announce the launch of AmnioVisc™, a minimally processed amniotic fluid supplement for the treatment of joint pain associated with...
Oct 11, 2016 08:00 am ET
Lattice Biologics Issues Common Shares Pursuant to Shares for Services Agreements
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICES Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) ("Lattice Biologics" or the "Company") is pleased to announce that it has issued 505,948 common shares of the Company (the...
Sep 15, 2016 04:35 pm ET
Lattice Biologics Closes First Tranche of Private Placement Announced on September 13, 2016
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICESLattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) ("Lattice Biologics" or the "Company") is pleased to announce that it has closed the first tranche of the non-brokered private...
Sep 13, 2016 05:09 pm ET
Lattice Biologics Announces New Private Placement and Eliminates Can$1.8 Million in Debt
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICESLattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) ("Lattice Biologics" or the "Company") is pleased to announce a private placement of Units of the Company (the "Units") at a...
Sep 06, 2016 08:00 am ET
New Vendor Approval Gives Lattice Biologics Access to 39 Additional Hospitals
Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) ("Lattice Biologics" or the "Company") announced today that it has been selected by another major healthcare services organization as an approved vendor. This not-for-profit public benefit...
Aug 29, 2016 06:05 pm ET
Lattice Biologics Ltd. Reports Third Quarter 2016 Highlights
Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) ("Lattice Biologics" or the "Company") announces financial results for the third quarter ended June 30, 2016: Third Quarter Financial Results (all figures denoted in USD):The Company strategy...
Aug 23, 2016 02:15 pm ET
Notice of Lattice Biologics Ltd. Third Quarter 2016 Financial Results Conference Call
Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) (the "Company") announced today it will release its third quarter 2016 financial results after market on Monday, August 29, 2016. Following this, Guy Cook, Chief Executive Officer, and Cheryl...
Aug 15, 2016 08:00 am ET
Lattice Biologics Issues Common Shares
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICESLattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) ("Lattice Biologics" or the "Company") is pleased to announce that it has obtained TSX Venture Exchange ("TSXV") approval to...
Aug 10, 2016 03:50 pm ET
Lattice Biologics Announces Planned Debt-to-Equity Conversion
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICESLattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) ("Lattice Biologics" or the "Company") announced today that, subject to approval by the TSX Venture Exchange, the Company will...
Aug 08, 2016 07:04 pm ET
Lattice Biologics Completes $500k Private Placement Announced on June 28, 2016
Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) ("Lattice Biologics" or the "Company") is pleased to announce that is has closed the second and final tranche of the partially brokered private placement of Units of the Company (the "Units")...
Aug 04, 2016 08:00 am ET
Giving Surgeons What They Want: 7 New Products From Lattice Biologics
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICESLattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) (the "Company") announced today 7 new biologic products as part of our ongoing commitment to deliver the highest quality...
Aug 01, 2016 08:00 am ET
Lattice Biologics Gains "Preferred Vendor Status" With the Veterans Health Administration (VHA)
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICESLattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) (the "Company") announced today that it has received preferred vendor status with the Veterans Health Administration (VHA), the...
Jul 15, 2016 04:30 pm ET
Lattice Biologics Announces Senior Management Change
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICESLattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) ("Lattice Biologics" or the "Company") announced today that Mr. Gregory Davis has resigned as Chief Operating Officer, effective...
Jun 30, 2016 05:50 pm ET
Lattice Biologics Closes First Tranche of Private Placement Announced on June 28, 2016
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICESLattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) ("Lattice Biologics" or the "Company") is pleased to announce that is has closed the first tranche of the partially brokered...
Jun 29, 2016 12:18 am ET
Lattice Biologics Announces New Private Placement
Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF)NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICESLattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) ("Lattice Biologics" or the "Company") is pleased to announce that it has...
Jun 20, 2016 08:00 am ET
Latest Vendor Approval Gives Lattice Biologics Access to Another 16 Hospitals
Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF)NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICESLattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) (the "Company") announced today that it has been selected by a major...
Jun 09, 2016 08:00 am ET
Major Southwest Hospital Group Designates Lattice Biologics as Approved Vendor
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICESLattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) (the "Company") announced today that it has been selected by a major hospital group in the southwest U.S. as an approved vendor....
May 26, 2016 06:00 pm ET
Lattice Biologics Ltd. Reports Second Quarter 2016 Highlights
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICES Lattice Biologics Ltd. (TSX VENTURE: LBL) ("Lattice Biologics" or the "Company") announces financial results for the second quarter ended March 31, 2016: Second...
May 20, 2016 08:00 am ET
Notice of Lattice Biologics Ltd. Second Quarter 2016 Financial Results Conference Call
Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) (the "Company") announced today it will release its second quarter 2016 financial results after the market on Thursday, May 26, 2016. Guy Cook, Chief Executive Officer, and Cheryl Farmer,...
Apr 18, 2016 07:00 am ET
Lattice Biologics Preparing to Launch Three New Products Featuring Matrix-Assisted Regeneration (MAR) Technology
Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) (Lattice Biologics) to launch three new products utilizing its patent pending matrix-assisted regeneration (MAR) platform. New products, MarBrane and MarGraft (expected to launch in...
Apr 15, 2016 09:00 am ET
Lattice Biologics Offering Exclusive Access to Revolutionary High-Throughput Precision Chemotherapy Screening for Breast Cancer
Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) is offering select breast reconstruction surgeons across the U.S. and Canada zero-cost access to what we aim to be the fastest and most clinically predictive cancer diagnostic. This...
Apr 01, 2016 09:00 am ET
Lattice Biologics Closes 60% of Private Placement Announced on March 18, 2016
Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) ("Lattice Biologics" or the "Company") is pleased to announce that is has closed the first tranche of the non-brokered private placement of special warrants of the Company (the...
Mar 30, 2016 09:00 am ET
Lattice Biologics and Sunnybrook Research Institute Commence Study to Develop New Cancer Screening Methods
Lattice Biologics Ltd. (TSX VENTURE: LBL)(OTCBB: BLVKF) ("Lattice Biologics" or the "Company") is pleased to announce it has entered into an Industry Sponsored Collaboration Agreement with Sunnybrook Research Institute ("SRI") in Toronto, Ontario...
Mar 18, 2016 09:00 am ET
Lattice Biologics Announces New Private Placement
Lattice Biologics Ltd. ("Lattice Biologics" or the "Company") (TSX VENTURE: LBL) is pleased to announce that is has negotiated a non-brokered private placement of special warrants of the Company (the "Special Warrants") at a price of CDN$0.30 per...
Mar 02, 2016 04:08 pm ET
IIROC Trading Resumption - LBL
VANCOUVER, March 2, 2016 /CNW/ - Trading resumes in:
Mar 02, 2016 03:40 pm ET
Lattice Biologics Announces Conversion of US$1.4 Million in Debt to Equity
Lattice Biologics Ltd. (TSX VENTURE: LBL) ("Lattice Biologics" or the "Company") is pleased to announce that approximately US$1.4 million of debt currently held by insiders of the Company will be converted to equity of Lattice...
Mar 02, 2016 02:10 pm ET
IIROC Trading Halt - LBL
VANCOUVER, March 2, 2016 /CNW/ - The following issues have been halted by IIROC:
Mar 01, 2016 01:16 pm ET
Lattice Biologics First Quarter 2016 Highlights
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICES Lattice Biologics Ltd. (TSX VENTURE: LBL) ("Lattice Biologics" or the "Company") announces financial results for the first quarter ended December 31, 2015:...
Feb 22, 2016 02:07 pm ET
Lattice Biologics Announces Grant of Stock Options
Lattice Biologics Ltd. (TSX VENTURE: LBL) ("Lattice Biologics" or the "Company") announces that it has granted an aggregate of 2,700,000 incentive stock options (the "Options") in accordance with the Company's stock option plan to...